Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study

Background The CombiVacS study was designed to assess immunogenicity and reactogenicity of the heterologous ChAdOx1-S/BNT162b2 combination, and 14-day results showed a strong immune response. The present secondary analysis addresses the evolution of humoral and cellular response up to day 180. Methods Between April 24 and 30, 2021, 676 adults primed with ChAdOx1-S were enrolled in five hospitals in Spain, and randomised to receive BNT162b2 as second dose (interventional group [IG]) or no vaccine (control group [CG]). Individuals from CG received BNT162b2 as second dose and also on day 28, as planned based on favourable results on day 14. Humoral immunogenicity, measured by immunoassay for SARS-CoV-2 receptor binding domain (RBD), antibody functionality using pseudovirus neutralisation assays for the reference (G614), Alpha, Beta, Delta, and Omicron variants, as well as cellular immune response using interferon-γ and IL-2 immunoassays were assessed at day 28 after BNT162b2 in both groups, at day 90 (planned only in the interventional group) and at day 180 (laboratory data cut-off on Nov 19, 2021). This study was registered with EudraCT (2021-001978-37) and ClinicalTrials.gov (NCT04860739). Findings In this secondary analysis, 664 individuals (441 from IG and 223 from CG) were included. At day 28 post vaccine, geometric mean titres (GMT) of RBD antibodies were 5616·91 BAU/mL (95% CI 5296·49–5956·71) in the IG and 7298·22 BAU/mL (6739·41–7903·37) in the CG (p 1:100 at day 180 (19% and 22%, respectively). Interpretation Titres of RBD antibodies decay over time, similar to homologous regimes. Our findings suggested that delaying administration of the second dose did not have a detrimental effect after vaccination and may have improved the response obtained. Lower neutralisation was observed against Omicron and Beta variants at day 180.Funded by Instituto de Salud Carlos III (ISCIII). AMB, AJC, JO, and JF are members of the VACCELERATE (European Corona Vaccine Trial Accelerator Platform) Network, which aims to facilitate and accelerate the design and implementation of COVID-19 phase 2 and 3 vaccine trials. JO is a member of the INsTRuCT (Innovative Training in Myeloid Regulatory Cell Therapy) Consortium, a network of European scientists from academia and industry focused on developing innovative immunotherapies. This work is funded by Instituto de Salud Carlos III, a Spanish public body assigned to the Ministry of Science and Innovation that manages and promotes public clinical research related to public health. The Spanish Clinical Trials Platform is a public network funded by the Instituto de Salud Carlos III (grant numbers PTC20/00018 and PT17/0017), the State Plan for Research, Development, and Innovation 2013–16, the State Plan for Scientific and Technical Research and Innovation 2017–20, and the Subdirectorate General for Evaluation and Promotion of Research, Instituto de Salud Carlos III, cofinanced with FEDER funds. CombiVacS was designed under the umbrella of the VACCELERATE project. VACCELERATE and INsTRuCT received funding from the EU's Horizon 2020 Research and Innovation Programme (grant agreement numbers 101037867 and 860003). The Instituto de Salud Carlos III is the Spanish partner in the VACCELERATE project. This work is partially funded by Institute of Health Carlos III (Instituto de Salud Carlos III – ISCIII –), (grants PI19CIII/00004 to JA and PI21CIII/00025 to MPO and JGP), and COVID-19 FUND (grants COV20/00679 and COV20/00072 to MPO and JA) and CIBERINFEC, co-financed by the European Regional Development Fund (FEDER) “A way to make Europe”

Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study

Background: The CombiVacS study was designed to assess immunogenicity and reactogenicity of the heterologous ChAdOx1-S/BNT162b2 combination, and 14-day results showed a strong immune response. The present secondary analysis addresses the evolution of humoral and cellular response up to day 180. Methods: Between April 24 and 30, 2021, 676 adults primed with ChAdOx1-S were enrolled in five hospitals in Spain, and randomised to receive BNT162b2 as second dose (interventional group [IG]) or no vaccine (control group [CG]). Individuals from CG received BNT162b2 as second dose and also on day 28, as planned based on favourable results on day 14. Humoral immunogenicity, measured by immunoassay for SARS-CoV-2 receptor binding domain (RBD), antibody functionality using pseudovirus neutralisation assays for the reference (G614), Alpha, Beta, Delta, and Omicron variants, as well as cellular immune response using interferon-γ and IL-2 immunoassays were assessed at day 28 after BNT162b2 in both groups, at day 90 (planned only in the interventional group) and at day 180 (laboratory data cut-off on Nov 19, 2021). This study was registered with EudraCT (2021-001978-37) and ClinicalTrials.gov (NCT04860739). Findings: In this secondary analysis, 664 individuals (441 from IG and 223 from CG) were included. At day 28 post vaccine, geometric mean titres (GMT) of RBD antibodies were 5616·91 BAU/mL (95% CI 5296·49-5956·71) in the IG and 7298·22 BAU/mL (6739·41-7903·37) in the CG (p 1:100 at day 180 (19% and 22%, respectively). Interpretation: Titres of RBD antibodies decay over time, similar to homologous regimes. Our findings suggested that delaying administration of the second dose did not have a detrimental effect after vaccination and may have improved the response obtained. Lower neutralisation was observed against Omicron and Beta variants at day 180.Funded by Instituto de Salud Carlos III (ISCIII). AMB, AJC, JO, and JF are members of the VACCELERATE (European Corona Vaccine Trial Accelerator Platform) Network, which aims to facilitate and accelerate the design and implementation of COVID-19 phase 2 and 3 vaccine trials. JO is a member of the INsTRuCT (Innovative Training in Myeloid Regulatory Cell Therapy) Consortium, a network of European scientists from academia and industry focused on developing innovative immunotherapies. This work is funded by Instituto de Salud Carlos III, a Spanish public body assigned to the Ministry of Science and Innovation that manages and promotes public clinical research related to public health. The Spanish Clinical Trials Platform is a public network funded by the Instituto de Salud Carlos III (grant numbers PTC20/00018 and PT17/0017), the State Plan for Research, Development, and Innovation 2013−16, the State Plan for Scientific and Technical Research and Innovation 2017−20, and the Subdirectorate General for Evaluation and Promotion of Research, Instituto de Salud Carlos III, cofinanced with FEDER funds. CombiVacS was designed under the umbrella of the VACCELERATE project. VACCELER ATE and INsTRuCT received funding from the EU’s Horizon 2020 Research and Innovation Programme (grant agreement numbers 101037867 and 860003). The Instituto de Salud Carlos III is the Spanish partner in the VACCELERATE project. This work is partially funded by Institute of Health Carlos III (Instituto de Salud Carlos III − ISCIII −), (grants PI19CIII/00004 to JA and PI21CIII/00025 to MPO and JGP), and COVID-19 FUND (grants COV20/00679 and COV20/00072 to MPO and JA) and CIBERINFEC, co-financed by the European Regional Development Fund (FEDER) “A way to make Europe”. The authors thank all trial participants, the international data safety monitoring board (Appendix 1 p 23), and the trial steering committee (Appendix 1 pp 24−25). The authors thank Esther Prieto for editorial assistance and writing support (employed by Hospital Universitario La Paz; funded by the Instituto de Salud Carlos III, grant number PCT20/00018) and María Castillo-de la Osa (PEJ2018-004557-A) for excellent technical assistance.S

Optimización de la línea de fangos en la EDAR Palma I

Este proyecto tiene como objetivo optimizar la línea de fangos de la estación depuradora Palma I. La EDAR Palma I consta de línea de gas, donde se produce electricidad para autoabastecerse e inyectar a la red eléctrica. El estudio previo al proyecto ha permitido identificar los dos puntos de principal interés de optimización. Por una parte, aumentar la producción de biogás. Se han realizado dos experimentos de codigestión anaerobia inyectando dos residuos diferentes en el digestor, aceites vegetales y bebidas azucaradas. Además, se ha estudiado la posibilidad de realizar la codigestión anaerobia con posidonia y residuos de patata. También, se ha comprobado el buen funcionamiento del proceso de digestión anaerobia en la planta. Por otra parte, la reducción de fangos producidos, esto significaría aumentar el porcentaje de materia seca obtenida a la salida de la línea; higienización de los fangos y la mejora añadida de incrementar también la producción de biogás. Para eso, se ha estudiado la posibilidad de implementar un proceso de hidrolisis térmica que permitiría un aumento del porcentaje de materia seca

La dramatització com a eina d’audició i llenguatge

[cat] L’ús de la dramatització al servei de la tasca educativa no es troba generalitzada en el context educatiu espanyol, tot i que diversos autors hagin assenyalat el gran nombre de beneficis que aquest suposa. Per aquest motiu, en el present treball es pretén conèixer i examinar les possibilitats de les tècniques dramàtiques per a la millora de la competència lingüística, més concretament de l’expressió oral. Es van comparar entre dos grups d’infants amb edats compreses entre els 9 i 11 anys en mesures de consciència fonològica. El grup experimental va participar durant un mes i mig en una experiència innovadora, realitzant un breu programa d’estimulació del llenguatge i la comunicació, fent ús de la dramatització. Es pretén comprovar si aquesta eina és útil, augmentant així les puntuacions entre la prova pretest i post-test pel que fa a la consciència fonològica. En la línia dels estudis previs, els resultats corroboren la hipòtesi plantejada i ressalten que després de realitzar les sessions, els infants del grup experimental han vist augmentats els seus resultats de manera significativa en totes les variables mesurables en termes de competència fonològica, en comparació al grup control que s’ha mantingut sense canvis. Per tant, es pot concloure que la dramatització suposa una millora en el treball de la consciència fonològica.[eng] The use of dramatization at the service of educational work is not widespread practice in the Spanish educational context, although several authors have pointed out the large number of benefits that this entails. For this reason, this paper aims to know and examine the possibilities of dramatic techniques for the improvement of linguistic competence, more specifically in oral expression. Two groups of children between the ages of 9 to 11 were compared in measures of phonological awareness. The experimental group was part of an innovative experience on language and communication stimulation though dramatization during one month and a half. It is intended to check if this tool is useful, thus increasing the scores between the pre-test and post-test with regard to the phonological awareness. In the line of previous studies, the results corroborate the departing hypothesis and emphasize that children of the experimental group increased significantly in all measurable variables in terms of phonological competence, compared to the control group, which showed no changes. Therefore, it can be concluded that dramatization represents an improvement in the work of phonological awareness

Optimització del funcionament del Fangs Activats de la EDAR I de Palma de Mallorca

El projecte consistirà en optimitzar el funcionament dels fangs activats en la EDAR I de Palma de Mallorca a través d'una retrospectiva tecnològica on l'objectiu serà disminuir la quantitats de fangs produïda en la depuradora

Les matemàtiques i la vida a l'aula

Resumen tomado de la publicación. El CD incluye la presentación del trabajo en documento pdf, archivo mht de 'Les matemàtiques i la vida a l'aula' y programa de instalación del Adobe Reader 7.0. El trabajo se llevó a cabo en el Seminario de Matemáticas de Educación Infantil del CEP de Palma en 2007Se presenta en formato Web las experiencias llevadas a cabo en las aulas de colegios públicos de Mallorca, relacionadas con las matemáticas en la Educación Infantil desde una perspectiva de la construcción del conocimiento por parte de los alumnos. Se incluyen imágenes de las actividades, observaciones, reflexiones y análisis de los procesos. La satisfacción que sienten los niños cuando son los protagonistas de sus propios aprendizajes es uno de los motores que cada día les hace seguir viajando hacia la comprensión del mundo.BalearesUniversitat de les Illes Balears. Redined Balears; Edifici Guillem Cifre de Colonya. Ctra. de Valldemossa, Km 7,5; 07122 Palma de Mallorca; +34971172792; +34971173190; [email protected]